On March 28, join us for interactive discussions featuring UCI scientists, clinicians, and community partners who are tackling colon cancer.

Dive into the science. Learn about screening & treatment. Leave connected.

Thursday, March 28, 2024
6:00 – 7:30pm
Sprague Hall, RM 105
839 Health Sciences Road
Irvine, CA 92697

Refreshments will be served. Parking free for guests who RSVP. Questions? Email cri@uci.edu

Speakers include:
Eric Hanse, PhD
Project Scientist

Oliver Eng M.D.,
Associate Professor, Surgery

Daniel Rivas, M.A.,
Director, Office of Community Outreach & Engagement (COE)
MORE ABOUT OUR SPEAKERS

Daniel Rivas, MA

*Director of the Office of Community Outreach and Engagement (COE)*

Daniel has an impressive background in project and operations leadership with over 20 years of experience helping non-profits, health care, and government groups crafting effective strategies to engage communities and fostering lasting relationships with community partners, including in his most recent role at Blue Shield of California. We look forward to his leadership in advancing our community outreach efforts.

Oliver Eng M.D.,

*Associate Professor, Surgery*

Dr. Oliver Eng is a board-certified UCI Health surgical oncologist who specializes in the treatment of peritoneal surface malignancies, metastatic malignancies, advanced gastrointestinal cancers, sarcomas, and neuroendocrine tumors. He is an expert on the treatment of cancers in the abdomen, particularly cancers that have spread to the peritoneum, the membrane that lines the abdominal cavity. He specializes in complex cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). HIPEC entails delivering high-dose heated chemotherapy in the operating room after surgical removal of visible disease and is effective in different types of cancers. Prior to joining UCI, Dr. Eng was on faculty at the University of Chicago, where he helped lead one of the most robust peritoneal surface malignancy programs in the country.

Eric Hanse, PhD

*Project Scientist*

[https://www.linkedin.com/in/eric-hanse-2257037/](https://www.linkedin.com/in/eric-hanse-2257037/)

Dr. Eric Hanse’s research focus is on understanding the biology of colorectal cancer (CRC). Specifically, he is interested in the Wingless and Int-1 (Wnt) signaling pathway as a therapeutic target for the disease, as it is estimated that up to 90% of CRC patients have disruptions in Wnt signaling. In a recent publication, he has helped identify that glutamine concentrations contribute to the advancement of CRC through Wnt and that supplementing glutamine or its subsequent metabolite, alpha-ketoglutarate, is sufficient to block Wnt signaling and tumor progression.